1. Bioceuticals Research Labs, Inc. Executive Summary March, 2010
Summary: Bioceuticals Research Inc. (BRI) is sustainably because our products deliver on their
creating a new market segment in the Personal Care promise. We have a plan to work collaboratively with
industry: Bioceuticals™ This market is huge: $40B, well established companies to license our technology
growing, and precedent transaction exit multiples to enhance their products through reformulation.
are 3-5 times revenues. With defensible disruptive Intellectual Property: Bioceutical Research Labs,
IP and a portfolio of patents, we have created a Inc. licenses intellectual property from a high
unique competitive advantage. technology company in Cambridge, MA. The primary
Industry: We are a specialty personal and health inventor, a Ph.D. Chemist (Yale), was on the
care company with products that enhance the skin Harvard Medical School faculty for over 25 years,
and body, improve vitality, and reduce the effects of has dozens of patents and published over 100
aging. Our products target unmet needs in these scientific papers. Our unique competitive advantage
categories by applying the science behind the Nobel is the transdermal delivery of L-Arginine, an
Prize in Medicine (1998). The market for our immediate precursor to nitric oxide (NO). Nitric
products will grow significantly because: oxide is known, through the 1998 Nobel Prize in
 Favorable Demographics, Teens to Boomers, Medicine, to enhance local blood flow and thus have
 Alternative Medicine is going mainstream, significant health benefits to the body.
 Nobel Prize in Medicine – high efficacy, Business Strategy: To become the #1 Bioceutical
 FDA and Pharma less credible, high risk. Products company in the personal care industry. We
Business: We uniquely apply patented technologies plan to leverage our “story:” the Nobel Prize in
to deliver all-natural highly efficacious ingredients to Medicine; Harvard patented technology; all natural
and through the skin and into the body. Our line of ingredients; and bone-fide efficacy.
creams based on a “dermal bridge”, are the only 1. Revitalize and Reposition the Brand: new
products with technology to improve the surface and identity, positioning, packaging, and web
sub-surface vitality of the skin, and the tissue below presence.
the skin. We currently have sales of $745K for 2009 2. Re-Launch existing product range in a multi-
up from $550K in 2008 or an increase of 27.6%. The channel of distribution including, brick and
Cosmeceutical market segment is $3.5b in 2009 and mortar, TV, direct, and internet.
projected to be $4b in 2010, an increase of 12.5%. 3. Extend current product range into systems
We are securing the license to this valuable that will drive multiple SKU purchases.
technology 4. Develop new personal care SKUs that can
Products: Cosmetics/Aesthetics: Lip Plumper, drive up to 60% of sales in the cosmetics
Breast lift (http://www.youtube.com/watch?v=udIwIW2QPvc), market. Leverage TV, internet content, and
Hair Grow, Celluflite, Firm Skin, Soft Nails, Shed community to drive adoption in drug,
Weight, Sandique Bioactive Skin Care Products grocery, and convenience.
Vitality: Sensation, Arousal 5. Develop single product, non-brand competing
Personal Care/Comfort: Healthy Feet, Warm Cream, private label programs for specialty retailer:
Pain Expeller, Cramp Expeller, Heal Sephora, Neiman Marcus, Victoria Secret,
Sports: Warm Up, Stretch, Work Out, Recover, Bulk J.C. Penny, etc..
Up, Massage, SportsShield 6. Implement an integrated marketing
Feet: Healthy Feet, Overnight Corn Salve, campaign across multiple forms of media: PR,
BlisterShield advertising, infomercials, internet, print, and
social media.
Market Opportunity: The personal care products 7. Drive brand awareness through sponsorship
industry includes about 750 companies with and valuate brand spokesperson
combined annual revenue of $40b. No one or two opportunities.
companies dominate a very fragmented market.
Most of the products sold are purely “cosmetic,” that Supply Chain: To become a “low cost” producer by
is, cover a defect, and driven by marketing, not by aligning with Tier 1 suppliers who are leaders in their
science or physiological efficacy. respective segments:
Bioceutical Research Labs Inc. markets a series of  Co-Packer: Chose a Tier 1 high speed tube
products that improve the appearance of the skin facility where we can achieve lowest fill cost
and contribute to improved health based on an and leverage ingredient and component
important physiological improvement in the body. purchasing with their purchasing power.
This is a significant departure from pure cosmetics.  Packaging: Develop proprietary and novel
We will penetrate the market and grab market share delivery systems for our unique products.
Bioceuticals Research Labs, Inc., 2010 Confidential All Rights Reserved

2. Bioceuticals Research Labs, Inc. Executive Summary March, 2010
Reduces commoditization of our products and From an Aesthetic perspective, delivery of L-Arginine
reinforces the uniqueness of our brand. results in significant improvement of the body and
 Warehouse/Transportation/Logistics: Secure skin. For instance, wrinkled skin becomes smoother,
ware-housing at a nominal cost from the co- more robust and supple with a reduction of sagging
packer. Transportation will be directed by and cellulite.
CHR, a publicly traded company, vendor of Studies: BRI has both objective and subjective
the year for Wal-Mart, P&G, Colgate, Target. evidence that our products provide the physiological
We will get freight rate 25-33% below benefits of L-Arginine. These data include proof that
independent carrier rates L-Arginine is delivered through the skin (PK Studies)
 Current COGS are 28%. We plan to reduce and that beneficial effects occur (skin warming of 5-
COGS to 24% by year end 2012.
8°F). In addition we have received numerous
Financing Sought and Use of Funds: We seek to positive testimonials.
raise a bridge loan of $2-$3Million for securing the Critical to realizing the benefits of L-Arginine is
IP, brand building, sales/marketing, inventory, and delivery of sufficient concentrations sub-dermally.
working capital requirements. We use the concept of fugacity to create a “dermal
Financial Projections: Bioceuticals Research Labs, bridge” and drive this amino acid efficiently and
Inc. had 2009 sales of $754K and a gross profit of effectively through the layers of the skin and into
72%. Year 1 will require an investment in IP, the local tissue and vascular systems. The material
licensing, sales, marketing, and operations. We will is delivered rapidly to the target tissue, often in less
than 1 minute. The beneficial effects of L-Arginine,
grow from projected sales of ~$3MM in Yr. 1 to
~$15MM by Yr.3. Net Profits Yr. 1 are projected to once delivered, lasts several hours.
be $70K growing to ~$3.5MM by the end of Yr. 3. Management Team:
$16 Bioceuticals Research Labs, Inc. has a seasoned
management team with deep industry and business
$14 Net Sales operating experience:
$12 CEO: Dan Silberberg has 30 years of bottom line
Gross Margins
P&L expertise running consumer product companies
$10 Net Income from $7-$400 million. Mr. Silberberg was CEO of
$ MM
$8 Globex Brands, Inc., a beverage company and
Crabtee & Evelyn.
$6 CTO: Dr. Tom Lewis holds a Ph.D. in Chemistry from
$4 MIT. He is the founder of several technology
companies and brings unique experience in leading
$2 research, business and new product development.
$- VP, Bus Dev: Rick Brutti has 30 years as an
entrepreneur, business consultant, assisting
2010-2011 2011-2012 2012-2013 companies raising capital, and financial mgt.
Chairman and Interim CFO: Malcolm Pirnie has a 30
Science: L-Arginine is a safe amino acid that is year finance background As CEO of Harbor Capital a
present in but not produced by the body. The impact $12B company sold to Fortis Investment, the
of L-Arginine and the benefits of judicious and Netherlands
optimal delivery are vast. The 1998 Nobel Prize in EVP Operation: Richard Erlanger has a 35 year track
Medicine revealed the importance of nitric oxide, of record in finance an operation.
which L-Arginine is a precursor, on blood vessel Sourcing Director: Larry Tronco has 35 years of
dilation and enhanced blood flow. Some of the experience as head of operations, Estee Lauder
proven benefits of appropriate and therapeutic levels Corp. and Crabtree & Evelyn. Mr. Tronco will act as
of L-Arginine include: an independent contractor.
1. Promotion of new cell growth Exit Strategy: We will realize a terminal value of 2-
2. Promotion of circulation resulting in 3 times revenues (precedent transactions). We have
Improved blood flow multiple options: Strategic, Global Player, PE Firm,
3. Improvement of immune function
Replacement Investor, IPO, or licensing agreement.
4. Reduction in healing time of injuries
5. Reduction of blood clots and stroke Contact: Dan Silberberg:781.223.4531;
6. Improved vascular function for patients dsilbe01@gmail.com
7. Prevention of cardiovascular disease Dr. Tom Lewis: 603.731.0992 tlewis@win-labs.com
Bioceuticals Research Labs, Inc., 2010 Confidential All Rights Reserved